Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinomaTing Zhou, Hongchao Li, Yingdan Cao et al.|BMC Health Services Research|2022Cited by 28